Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Page 243

Circle Pharma draws $66m series C

The oncology therapeutics developer has added $66m to its coffers thanks to investors including Berkeley Catalyst Fund.

Jun 18, 2021

Flagship charges ahead with $3.37bn

Flagship Pioneering has re-opened its Fund VII to raise an additional $2.23bn that brought the vehicle’s total capital to $3.37bn.

Jun 18, 2021

Claroty counts on corporates to raise $140m

Standard Industries' 40 North unit co-led a series D round that included LG, Schneider Electric, Rockwell Automation and Siemens at a reported $1bn-plus valuation.

Jun 18, 2021

Bringg fetches $100m at a $1bn valuation

GLP, Salesforce Ventures and Siemens' Next 47 unit all participated in a series E round that lifted the fulfilment software provider's overall funding to over $180m.

Jun 18, 2021

Amplitude raises $163m for debut fund

Limited partners including Alexandria Venture Investments and Royal Bank of Canada backed the healthcare technology-focused firm's first fund.

Jun 18, 2021

Singh leaves JetBlue for JLL

As managing partner at JLL Spark, Singh will help manage the property technology investment fund.

Jun 18, 2021

Daily Deal Round Up: June 17, 2021

11Street and CJ Group contributed to a $71.8m round for on-demand logistics provider Barogo while Eli Lilly helped provide $66m for macrocycle drug developer Circle Pharma.

Jun 17, 2021

Waymo drives through to $2.5bn round

Alphabet, AutoNation and Magna International all returned to reinvest in the driverless car technology developer having backed a $3.2bn round last year.

Jun 17, 2021

Marqeta marks off $1.41bn initial public offering

The payment card technology provider, which counts Visa, CommerzBank, CreditEase and Mastercard as investors, has added about $190m to close its IPO.

Jun 17, 2021

Verve Therapeutics beats its way to $267m IPO

Broad Institute and UPenn-linked cardiovascular disease drug developer Verve priced an upscaled initial public offering above its range.

Jun 17, 2021
© 2025 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here